Phase IIb trial of a high-dose, continuous delivery formulation of subcutaneously administered levodopa/carbidopa (ND0612H) in patients with Parkinson's disease.

Trial Profile

Phase IIb trial of a high-dose, continuous delivery formulation of subcutaneously administered levodopa/carbidopa (ND0612H) in patients with Parkinson's disease.

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2015

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors NeuroDerm
  • Most Recent Events

    • 23 Nov 2015 Planned initiation date changed from 1 Jul 2015 to 1 Dec 2015.
    • 12 Nov 2015 According to the media release of NeuroDerm Ltd., this trial will be initiated by the end of 2015 or in the beginning of 2016.
    • 12 Nov 2015 According to the media release of NeuroDerm Ltd., the company has incorporated the written feedback received from U.S. Food and Drug Administration (FDA). Also, this trial will be conducted at centers in Israel, E.U and U.S.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top